Navigation Links
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
Date:10/6/2008

Vice President and Chief Medical Officer at Ironwood.

"These novel findings provide valuable insight into the possible role of cGMP in alleviating intestinal pain and may explain the reduction in intestinal pain observed in patients with IBS-C treated with linaclotide in our Phase 2b studies," said Mark Currie, Ph.D., Senior Vice President, R&D and Chief Scientific Officer at Ironwood.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide reduced abdominal pain and relieved constipation-the hallmarks of the condition-throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week study period. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Healthcare costs associated with IBS exceed $25 billion ann
'/>"/>

SOURCE Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... CVS Caremark (NYSE: CVS ) today ... of CVS/pharmacy effective October 1, 2011.  With more than ... and Puerto Rico, CVS/pharmacy is one of the largest ... http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) Cosby, 52, most recently served as ...
... Oncobiologics, Inc. and Fox Chase Cancer Center ... next-generation bi-specific antibody cancer platform with enhanced therapeutic ... is designed to handle multiple targets, representing a ... is now underway, with preclinical studies expected in ...
Cached Medicine Technology:CVS Caremark Appoints Mark S. Cosby as President of CVS/pharmacy 2CVS Caremark Appoints Mark S. Cosby as President of CVS/pharmacy 3Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform 2Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform 3
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... bottom of Alzheimer,s disease has been a rapidly ... In the latest crook in the research road, ... interaction between proteins associated with the disease. The ... Chemical Neuroscience , could have important implications for ... Nieznanski and colleagues explain that for years, research ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to reduce ... as 50 percent. When coupled with an innovative electrode ... device facilitated the complete elimination of seizures in nearly ... decade-long clinical trials. , That,s good news for a ... U.S. living with epilepsy whose seizures can,t be controlled ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... April 22, 2014: The Association for Molecular Pathology ... Journal of Molecular Diagnostics on recommendations for ... and master,s levels of education. The report was ... Task Force of the AMP Training and Education ... need of educating future medical laboratory scientists appropriately ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... , ... firm Jackson & Coker ranked #3 on SIA’s 2009 list of “Ten Best Staffing ... , ... December 11, 2009 -- Each year, Staffing Industry Analysts, a premier research and analysts ...
... The Phoenix Business Journal and BestCompaniesAZ, co-founders ... SCAN Health Plan Arizona has been named to the 2009 ... employees, who provided extensive insight into employee life. , SCAN ... culture and work environment that fosters personal and professional growth ...
... estrogen-positive tumors, study found , THURSDAY, Dec. 10 ... tamoxifen can boost survival in postmenopausal women with ... as estrogen receptor-positive, and it,s best given before ... study. , "Chemotherapy with Adriamycin adds to your ...
... , U.S. Rep. Gerry Connolly (D-Va.) Also to ... 10 The Federal Employees Health Benefits Plan (FEHBP) open enrollment period ... (AFGE) "Inside Government" radio program. The show will air on Friday, ... www.federalnewsradio.com and 1500 AM in the ...
... , DETROIT, Dec. 10 African-American political leaders, ... Monday, December 14th to create and implement a ... African-American Community. , "Detroit is leading the nation ... the Rev. Horace Sheffield III, National Board Member and ...
... to prevent recurrence, researchers find , THURSDAY, Dec. 10 ... millions of women to fight osteoporosis also cut the ... a dual role in keeping women healthy. , ... of breast cancer therapy. Our feeling is that bisphosphonates ...
Cached Medicine News:Health News:Jackson & Coker Ranks #3 among “Ten Best Staffing Firms to Work For” 2Health News:Jackson & Coker Ranks #3 among “Ten Best Staffing Firms to Work For” 3Health News:Jackson & Coker Ranks #3 among “Ten Best Staffing Firms to Work For” 4Health News:SCAN Health Plan Arizona Named one of Area's Best Places to Work by the Phoenix Business Journal and BestCompaniesAZ, LLC 2Health News:Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients 2Health News:Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients 3Health News:FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government' 2Health News:Black Community Unites Against HIV/AIDS Epidemic 2Health News:Bone Drugs May Beat Back Breast Cancer 2
White Standard Girdle...
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper...
Short Girdle, Mid-thigh, Front Closure...
Male Body Shaper, Front Closure...
Medicine Products: